NexImmune (NEXI) has released an update to notify the public and investors about a termination of a material definitive agreement.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
NexImmune, Inc. had an agreement with Cantor Fitzgerald & Co. and BTIG, LLC to sell shares of common stock through an “at the market” program, aiming to raise up to $50 million. They terminated the agreement on February 2, 2024, without incurring material penalties. Before termination, NexImmune sold 127,396 shares, netting approximately $5.1 million.
For further insights into NEXI stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
